• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BMS 不良反应的炎症机制。

Inflammatory mechanisms of adverse reactions to BMS.

机构信息

First Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece.

出版信息

Curr Vasc Pharmacol. 2013 Jul;11(4):379-91. doi: 10.2174/1570161111311040002.

DOI:10.2174/1570161111311040002
PMID:23905633
Abstract

Adverse reactions to bare metal stent implantation include stent thrombosis and restenosis. Although thrombosis in bare metal stents seems mainly to be affected by procedural factors, restenosis is a more complex procedure involving mechanisms of tissue repair after vessel injury occurring during implantation. This procedure includes early platelet and leukocyte invasion, followed by smooth muscle cell proliferation, as well as further inflammatory cell recruitment mediated by expression of chemokines and leukocyte activation at the site of the injury. In this report, we will focus on the role of inflammation in the development of in-stent restenosis in bare metal stents. In particular, we will describe the pathologic evidence implicating inflammatory cell involvement in the development of restenosis in animal and human models; we will analyze the molecular mechanisms linking inflammation with restenosis; and will review the association of pre-existing or procedure-induced systemic inflammation with adverse reactions at follow-up.

摘要

支架内再狭窄是指支架内出现的新生动脉粥样硬化斑块,导致血管管腔再次狭窄。

相似文献

1
Inflammatory mechanisms of adverse reactions to BMS.BMS 不良反应的炎症机制。
Curr Vasc Pharmacol. 2013 Jul;11(4):379-91. doi: 10.2174/1570161111311040002.
2
Inflammatory mechanisms of adverse reactions to drug-eluting stents.药物洗脱支架不良反应的炎症机制。
Curr Vasc Pharmacol. 2013 Jul;11(4):392-8. doi: 10.2174/1570161111311040003.
3
The evolving role of inflammatory biomarkers in risk assessment after stent implantation.支架植入术后炎症生物标志物在风险评估中的作用演变。
J Am Coll Cardiol. 2010 Nov 23;56(22):1783-93. doi: 10.1016/j.jacc.2010.06.045.
4
Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.血管损伤和支架置入后平滑肌细胞增殖和内皮再生的机制:治疗方法。
Circ J. 2011;75(6):1287-96. doi: 10.1253/circj.cj-11-0366. Epub 2011 Apr 29.
5
Integrity(®) bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience(®) everolimus-eluting stents in stable angina patients.在稳定型心绞痛患者中,与Xience®依维莫司洗脱支架相比,Integrity(®)裸金属冠状动脉支架引起的血小板和内皮细胞活化导致再狭窄风险更高。
Platelets. 2016 Jul;27(5):410-9. doi: 10.3109/09537104.2015.1112368. Epub 2016 Jan 14.
6
[Clinical value of inflammatory biomarkers after stent implantation].[支架植入术后炎症生物标志物的临床价值]
G Ital Cardiol (Rome). 2011 Oct;12(10):635-44. doi: 10.1714/945.10348.
7
Intimal proliferation and restenosis in paclitaxel-eluting stents with aminoparylene as carrier substance in swines.以氨基聚对二甲苯为载体物质的猪用紫杉醇洗脱支架的内膜增生和再狭窄
J Invasive Cardiol. 2009 Mar;21(3):128-32.
8
Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents.因症状性支架内再狭窄住院并接受经皮冠状动脉介入治疗患者的临床表现及预后:药物洗脱支架与裸金属支架的比较
Arch Cardiovasc Dis. 2009 Mar;102(3):209-17. doi: 10.1016/j.acvd.2009.01.004. Epub 2009 Mar 17.
9
Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.西罗莫司洗脱支架和裸金属支架植入后的晚期不良事件:冠状动脉血运重建显示结局研究-京都注册队列-2 的长期(5-7 年)随访。
Circ Cardiovasc Interv. 2014 Apr;7(2):168-79. doi: 10.1161/CIRCINTERVENTIONS.113.000987. Epub 2014 Feb 18.
10
Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.裸金属支架置入术后基于导管的紫杉醇给药与药物洗脱支架在冠状动脉疾病支架内再狭窄高危患者中的比较。
Cardiovasc Revasc Med. 2017 Dec;18(8):596-600. doi: 10.1016/j.carrev.2017.05.018. Epub 2017 May 31.

引用本文的文献

1
Inflammation-Controlled Anti-Inflammatory Hydrogels.炎症控制型抗炎水凝胶。
Adv Sci (Weinh). 2023 Mar;10(7):e2206412. doi: 10.1002/advs.202206412. Epub 2022 Dec 29.
2
The use of CD47-modified biomaterials to mitigate the immune response.使用经CD47修饰的生物材料来减轻免疫反应。
Exp Biol Med (Maywood). 2016 May;241(10):1033-41. doi: 10.1177/1535370216647130. Epub 2016 May 10.
3
Enhanced biocompatibility of CD47-functionalized vascular stents.CD47功能化血管支架的生物相容性增强
Biomaterials. 2016 May;87:82-92. doi: 10.1016/j.biomaterials.2016.02.008. Epub 2016 Feb 8.
4
OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease.光学相干断层扫描显示新生动脉粥样硬化是冠状动脉疾病持续过程的一部分。
Herz. 2015 Sep;40(6):845-54. doi: 10.1007/s00059-015-4343-y.